A world-renowned diabetes researcher has joined Wendy Novak Diabetes Institute, a part of Norton Healthcare and Norton Children’s, with the goal of curing Type 1 diabetes. Balamurugan N. Appakalai, Ph.D., also known as Dr. Bala, is a leading researcher in islet cell transplants and is widely considered one of the most skilled islet isolation specialists…
An internationally known researcher is joining Wendy Novak Diabetes Institute, a part of Norton Healthcare and Norton Children’s, with the goal of curing Type 1 diabetes. Norton Healthcare and Norton Children’s announced plans to build a specialized laboratory to help him and his team carry out their groundbreaking work and become a hub for diabetes research…
Patients 18 years of age and older with cystic fibrosis now have an option of participating in a Phase 1 trial of a novel, broad-spectrum, orally delivered enzyme replacement therapy for cystic fibrosis (CF). The randomized, active-treatment trial is testing the safety, tolerability and effect of four dose levels of ANG003, a compound developed by…
Norton Healthcare has launched a new, open-access medical journal to promote the sharing of innovation and ideas from the laboratory, the bedside and everyday practice. Norton Healthcare Medical Journal welcomes original articles related to medicine, nursing, public health, pharmacy and dentistry, across the full continuum of health care for adult and pediatric populations. The no-cost-to-publish,…
Louisville Business First has recognized researchers at Norton Healthcare with its 2024 Health Care Heroes Innovator Award. The award honors those who break ground in the health care field by developing or implementing new technology, treatments or programs with wide applications. Award recipients were: Manager Award This award honors leaders ranging from the head of a small…
Reviewed by Amber L. Pendleton, M.D. Implementing the principles of trauma-informed care across a primary care team and community resources provides an opportunity to focus on adverse childhood experiences and social-care needs, with the potential to improve lifelong health. Norton Children’s Medical Group, affiliated with the UofL School of Medicine, embarked on a program to…
Clinical trials and studies, which are essential to the development of new drugs and treatments, need to be conducted under strict ethical, clinical and investigational structures. The most common are investigational trials with new medications or new devices. There are also studies involving outcome measurements and those looking at how people most effectively manage disease….
Norton Children’s Research Institute, affiliated with the UofL School of Medicine, is involved in a study to evaluate the safety, pharmacokinetics and efficacy of nirmatrelvir/ritonavir (authorized as Paxlovid in older children and adults) in symptomatic pediatric outpatients with COVID-19 who are at risk of progression to severe illness. All participants will receive the study medication,…
Clinical research drives progress for every element of health and requires global collaboration. At Norton Healthcare alone, our research teams lead and contribute to studies about pediatric medicine, cancer, infectious diseases, cardiology, neurology, the spine, orthopedics and many other specialties. Research requires meticulous attention to detail and a strong commitment to ethical integrity, not to…
Cadmium, a natural element used for rechargeable batteries and other industrial applications, can induce a novel type of testicular cell death in mice after low-dose exposure, according to a groundbreaking study. Cadmium is known to bioaccumulate and is linked to many health disorders, including male infertility. The study discovered low-dose cadmium exposure induces damage in…
Anti-CD20 monoclonal antibody therapy represents a major advance in treating relapsing multiple sclerosis (MS) in adult patients, reducing relapse risk and mitigating disability progression. These monoclonal antibody therapies deplete circulating B cells by targeting CD20, a surface marker expressed on pre-B cells, naïve B cells and memory B cells. A review article in CNS Drugs,…
A low-toxicity myeloablative conditioning regimen is safe and effective in treating high-risk leukemias, particularly myeloid disease, according to a study recently published in the journal Pediatric Blood & Cancer. Conventional myeloablative conditioning is effective at reducing the risk of a relapse in pediatric hematologic malignancy patients who are undergoing allogeneic hematopoietic stem cell transplant (HCT)….